The Pill That Could Rescue Myeloma Patients After Everything Else Fails

CellCentric's Phase 2 dose optimization data, presented in December 2025, showed a 75% overall response rate in the pomalidomide-refractory post-BCMA/TCE subgroup at the 30 mg dose. The patients in that study were heavily pretreated, with a median of five prior therapy lines. Many were refractory to pomalidomide and had already been through BCMA-targeted treatments (the latest generation of myeloma drugs).

For context, real-world response rates for similar patients on available alternatives hover around 25-30%. So inobrodib roughly doubled or tripled what doctors expect to see in this population.

That's the kind of data that makes venture capitalists reach for their checkbooks.

The Road Ahead: DOMMINO Falls Into Place

The $220 million funds two key trials. DOMMINO-1, a pivotal Phase 2 study combining inobrodib (at 20 mg) with pomalidomide and dexamethasone, began enrolling in March 2026. The first patient was dosed at The Royal Marsden in London, with U.S. sites also active.

Then comes DOMMINO-2, a global Phase 3 trial planned for the second half of 2026. Together, these form a full registration program: the kind of clinical package you'd bring to the FDA when asking for approval.

The target population is patients whose cancer progressed after bispecific antibodies or anti-BCMA therapy. About half of bispecific-treated patients eventually relapse, and roughly a third never respond at all. These patients have very few options left. An all-oral regimen they can take at home (rather than traveling to infusion centers) would be genuinely transformative for their quality of life.

Why This Feels Different From the Usual Hype

Let's be honest: biotech is littered with $200 million raises that led nowhere. What makes CellCentric's story more compelling?

First, the syndicate quality. This isn't a single investor making a big bet. Venrock led, but Fidelity, RA Capital, Forbion, Sofinnova, and HBM all participated. When that many sophisticated healthcare investors independently underwrite the same thesis, it carries weight. RA Capital and Forbion already co-led the $120 million Series C, so they've seen the data up close and doubled down.

Second, Pfizer is on the cap table. A major pharma company investing in a clinical-stage myeloma asset signals potential partnership or acquisition interest down the line. It's not confirmation of a deal, but it's a breadcrumb worth noticing.

Third, the mechanism is genuinely first-in-class. In a myeloma landscape increasingly crowded with bispecifics and CAR-T therapies (all targeting similar immune pathways), a completely orthogonal approach fills a real gap. The market for next-generation myeloma drugs is projected to reach $37 billion by 2033, but most of that growth is concentrated in biologics and cell therapies. An oral small molecule with a novel mechanism occupies a unique lane.

The Elephant in the Room

The competitive landscape is brutal. Johnson & Johnson, Bristol Myers Squibb, Regeneron, Sanofi, Legend Biotech, and Pfizer itself all have approved or late-stage myeloma products. Over 75 companies are developing 80-plus pipeline drugs in this space.

But here's CellCentric's argument: they're not competing head-to-head with CAR-T or bispecifics. They're positioned as what comes after those treatments fail. That's a growing population as more patients receive immunotherapies earlier in their disease course. The more patients who get bispecifics in second line, the more patients who'll eventually need something like inobrodib in fourth or fifth line.

It's a counterintuitive dynamic: your competitors' success actually grows your market.

What Comes Next

CellCentric CEO Will West has signaled that the company is positioning for a potential IPO. The Series D gives them runway through pivotal data readouts, and a strong public debut would depend on DOMMINO-1 showing convincing efficacy in the registration-enabling portion.

For now, the company is heads-down enrolling patients. If the Phase 3 data replicate what they saw in Phase 2 (and that's always a big "if" in oncology), CellCentric could have a genuinely differentiated product in a market desperate for new options.

A pill. Taken at home. For patients who've run out of alternatives. Sometimes the simplest ideas are the hardest to execute, and the most valuable when they work.

Amgen Just Bet on a Computer That Doesn't Fully Exist Yet

Quantinuum, a quantum computing company backed by Amgen and valued at $10 billion, just filed for what could be the largest quantum IPO ever. The real story: Amgen is betting quantum computers can fundamentally redesign how drugs get discovered.